ArticleNPJ breast cancer2023

Pak1 pathway hyper-activation mediates resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer.

Stefania Belli et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.